Is the Patent System a Barrier to Inclusive Prosperity? The Biomedical Perspective

Helen Gubby

Global Policy, 2020, vol. 11, issue 1, 46-55

Abstract: As patents grant monopolies, the patent system has a considerable impact on markets. When corporations use certain patent strategies, social welfare can be damaged. This article focuses on how corporations use patent strategies in the biomedical sector. Strategic patenting makes it possible to extend monopolies beyond the designated period and block competitors. Access to fundamental research can be restricted. Patients are disadvantaged by high monopoly prices for drugs, which can mean exclusion from treatment. It is argued here that as biomedical technologies are so vital to the welfare of people, and that in some cases are literally a matter of life or death for patients, this area of technology should not be controlled by private companies through their patent monopolies. The whole biomedical sector should be taken out of the ambit of the patent system.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://doi.org/10.1111/1758-5899.12730

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:bla:glopol:v:11:y:2020:i:1:p:46-55

Ordering information: This journal article can be ordered from
http://www.blackwell ... bs.asp?ref=1758-5880

Access Statistics for this article

Global Policy is currently edited by David Held, Patrick Dunleavy and Eva-Maria Nag

More articles in Global Policy from London School of Economics and Political Science Contact information at EDIRC.
Bibliographic data for series maintained by Wiley Content Delivery ().